Testosterone replacement therapy for late-onset hypogonadism: Current trends in Korea

Asian Journal of Andrology

Volumn 13, Issue 4, 2011, Pages 563-568

  Ko, Young Hwii ^a   Kim, Je Jong ^a  

^a Korea University Ansan Hospital   (South Korea)

Author keywords

androgenic agents; androgens; late onset hypogonadism; testosterone replacement therapy

Indexed keywords

TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ACNE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; DRUG CONTRAINDICATION; DRUG EFFICACY; DYSPNEA; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPOGONADISM; KOREA; MALE; MICTURITION DISORDER; NOCTURIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGING; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; KOREA; MALE; TESTOSTERONE;

EID: 79960048496     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.124     Document Type: Review

References (64)

1. Morales A, Heaton JP, CarsonCC 3rd. Andropause: a misnomer for a true clinical entity. J Urol 2000; 163: 705-12.
2. Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur Urol 2000; 38: 655-62.
3. Park MG, Kang SC, Lee TW, Lee J, Kang SHet al. Attitude of Korean males toward lateonset hypogonadism: survey of males in their 40s and above. Korean J Androl 2007; 25: 26-31.
4. Kim MJ, Rhee Y, Seo JT, Yang DY, Moon DG et al. 2006 KOSAR recommendations for investigation, treatment and monitoring of LOH in males. Korean J Androl 2008; 26: 8-10.
5. Kubricht WS 3rd, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 1999; 54: 1035-8.
6. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006; 91: 4326-34. (Pubitemid 44833406)
7. Heald AH, Ivison F, Anderson SG, Cruickshank K, Laing I et al. Significant ethnic variation in total and free testosterone concentration. Clin Endocrinol 2003; 58: 262-6. (Pubitemid 36308112)
8. van Houten ME, Gooren LJ. Differences in reproductive endocrinology between Asian men and Caucasian men-a literature review. Asian J Androl 2000; 2: 13-20.
9. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E et al. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab 2004; 89: 2936-41. (Pubitemid 38766388)
10. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ et al. Investigation, treatment and monitoring of lateonset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-14.
11. Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 2006; 3: 1085-9. (Pubitemid 44644721)
12. Hong JH, Ahn TY. Oral testosterone replacement in Korean patients with PADAM. Aging Male 2002; 5: 52-6. (Pubitemid 34587558)
13. Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 2003; 6: 86-93. (Pubitemid 36936510)
14. Seo KK, Yoon SH, Kim SC. Efficacy and safety of Androderm2in partially androgendeficient aging men with erectile dysfunction. Korean J Androl 1998; 16: 79-85.
15. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212-5. (Pubitemid 24218140)
16. Bae JH, Lee J, Kim JW, Kim NS, Yoon JH et al. Oral testosterone undecanoate (AndriolH) for increasing serum testosterone level in late onset hypogonadism patients. Korean J Androl 2005; 23: 127-32.
17. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56-8. (Pubitemid 40978894)
18. Park JS, Hong JI, Park NC. Changes in the quality of life after tansdermal testosterone (Androderm) supplement therapy in the aging male. Korean J Urol 1999; 40: 1057-65.
19. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 2010; 121: 513-9.
20. Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Pyschiatry 2005; 66: 7-14.
21. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 2005; 8: 59-74.
22. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001; 137: 231-43. (Pubitemid 32296061)
23. Morley JE, Perry HM III, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006; 53: 424-9.
24. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004; 7: 211-8. (Pubitemid 39315125)
25. Park HJ, Park BK, Kim JM, Park NC. The relationship between serum total testosterone and clinical symptoms of late-onset hypogonadism in aging males. Korean J Androl 2006; 24: 35-9.
26. Park DS, Kim TB, Ku JH, Kim SW, Paick JS. Correlation between Androgen Deficiency on the Aging Males Questionnaire and the Aging Males Symptoms Scale and their relationship with serum testosterone. Korean J Urol 2008; 49: 1035-40.
27. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42.
28. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
29. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-43. (Pubitemid 44833407)
30. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813-17. (Pubitemid 39071477)
31. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 2006; 65: 275-81.
32. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
33. Seftel A. Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007; 19: 2-24. (Pubitemid 46067343)
34. Park NC, Seo JT, Moon KH, Park KS, Park JK et al. Efficacy and safety of testosterone gel in Korean men with late-onset hypogonadism: a prospective, fixed-dose, placebo-uncontrolled, open-label, multicenter study. Korean J Androl 2007; 25: 103-11.
35. Bae JH, Kim NS, Kim JW, Park MG, Kim MJ et al. The efficacy of transdermal testosterone (Testogel) in late onset hypogonadism patients: changes in serum testosterone level and symptom scores based on Aging Males Symptoms Scale. Korean J Androl 2006; 24: 115-25.
36. Comhaire FH. Andropause: hormone replacement therapy in the aging male. Eur Urol 2000; 38: 655-62.
37. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M et al. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria. Aging Male 2006; 9: 221-7.
38. Bae JH, Yu JW, Kim JJ, Moon DG. Clinical efficacy and safety of long-acting injectable testosterone undecanoate for treating patients with testosterone deficiency syndrome. Korean J Androl 2008; 26: 227-33.
39. Moon DG, Park MG, Lee SW, Park K, Park JK et al. The efficacy and safety of testosterone undecanoate (Nebido) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010; 7: 2253-60.
40. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991; 53: 363-74.
41. Travison TG, Morley JE, Araujo AB, ODonnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91: 2509-13. (Pubitemid 44024610)
42. Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA. Frailty and the aging male. Aging Male 2005; 8: 135-40. (Pubitemid 43068301)
43. Aversa A, Isidori AM, de Martino MU, Caprio M, Fabbrini E et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol 2000; 53: 517-22.
44. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 58: 632-8. (Pubitemid 36566807)
45. Park MG, Park SH, Ko KW, Ham BK, Kim JJ et al. The efficacy of a combination of phosphodiesterase type 5 inhibitor and testosterone replacement therapy in nonresponders to phosphodiesterase type 5 inhibitor mono-therapy. Korean J Androl 2009; 27: 25-30.
46. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009; 4: 397-412..
47. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
48. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New Engl J Med 2004; 350: 482-92. (Pubitemid 38133769)
49. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ et al. Effect of testosterone replacement therapy on prostate tissue im men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351-61. (Pubitemid 44749363)
50. Barqawi A, Crawford ED. Testosterone replacement therapy and risk of prostate cancer. Is there a link? Int J Impot Research 2006; 18: 323-8.
51. Coward RM, Simhan J, Carson CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009; 103: 1179-83.
52. Lee KH, Choi YH, Cho SY, Lee KC, Cho IR. Prostate safety of androgen replacement therapy focusing on prostate specific antigen. Korean J Androl 2008; 26: 24-8.
53. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44. (Pubitemid 32771319)
54. Litman HJ, Bhasin S, OLeary MP, Link CL, McKinlay JB et al. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int 2007; 100: 321-6. (Pubitemid 47036575)
55. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in communitydwelling older men. BJU Int 2010; 105: 1554-9.
56. Karazindiyanog?lu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008 11 146-9
57. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with lateonset hypogonadism: a pilot study. Aging Male 2008; 11: 57-61. (Pubitemid 351878773)
58. Sohn DW, Lee BH, Choe HS, Kim SD, Kim DB et al. Correlation between serum testosterone and lower urinary tract symptoms in men with hypogonadism symptoms. Korean J Androl 2008; 26: 91-5.
59. Lee MW, Park JK. Study of prostate volume, age, serum prostate specific antigen and testosterone in patients with benign prostate hyperplasia with lower urinary tract symptoms. Korean J Androl 2005; 23: 133-7.
60. Kim SC, Chang IH, Kwon YW, Ha MS. A possible relationship between testosterone and lower urinary trant symptoms in men. J Urol 2010; 183 (Suppl): 277.
61. Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N et al. Endogenous testosterone and mortality from all causes, CV disease and cancer in men: EPICNorfolk prospective population study. Circulation 2007; 116: 2694-701.
62. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009; 161: 443-9.
63. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-6. (Pubitemid 39005930)
64. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.